Association between global biomarkers of oxidative stress and hip fracture in postmenopausal women: A prospective study

Journal of Bone and Mineral Research

Volumn 29, Issue 12, 2014, Pages 2577-2583

  Yang, Shuman ^a   Feskanich, Diane ^c   Willett, Walter C ^b,c   Eliassen, A Heather ^b,c   Wu, Tianying ^a  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Fluorescent oxidation products; Hip fracture; Oxidative stress; Postmenopausal women

Indexed keywords

BIOLOGICAL MARKER; DNA; FLUORESCENT OXIDATION PRODUCT; LIPID; MALONALDEHYDE; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIP FRACTURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; OSTEOPOROSIS; OXIDATIVE STRESS; POSTMENOPAUSE; PROSPECTIVE STUDY; RISK FACTOR; SMOKING; AGED; BLOOD; CLINICAL TRIAL; HIP FRACTURES; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; BIOMARKERS; FEMALE; FOLLOW-UP STUDIES; HIP FRACTURES; HUMANS; MIDDLE AGED; OXIDATIVE STRESS; POSTMENOPAUSE; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84918587890     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2302     Document Type: Article

References (34)

1. Holvoet P. Oxidized LDL and coronary heart disease. Acta Cardiol. 2004;59(5): 479-84.
2. Koenig W, Karakas M, Zierer A, Herder C, Baumert J, Meisinger C, et al. Oxidized LDL and the risk of coronary heart disease: Results from the MONICA/KORA Augsburg Study. Clin Chem. 2011;57(8): 1196-200.
3. Southorn PA, Powis G. Free radicals in medicine. II. Involvement in human disease. Mayo Clin Proc. 1988;63(4): 390-408.
4. Jensen MK, Wang Y, Rimm EB, Townsend MK, Willett W, Wu T. Fluorescent oxidation products and risk of coronary heart disease: A prospective study in women. J Am Heart Assoc. 2013;2(5): E000195.
5. Wu T, Rifai N, Willett WC, Rimm EB. Plasma fluorescent oxidation products: Independent predictors of coronary heart disease in men. Am J Epidemiol. 2007;166(5): 544-51.
6. Fortner RT, Tworoger SS, Wu T, Eliassen AH. Plasma florescent oxidation products and breast cancer risk: Repeated measures in the Nurses' Health Study. Breast Cancer Res Treat. 2013;141(2): 307-16.
7. Bai XC, Lu D, Bai J, et al. Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-kappaB. Biochem Biophys Res Commun. 2004;314(1): 197-207.
8. Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radical Biology and Medicine. 2001;31(4): 509-19.
9. Almeida M, Han L, Martin-Millan M, et al. Skeletal involution by ageassociated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem. 2007;282(37): 27285-97.
10. Sanchez-Rodriguez MA, Ruiz-Ramos M, Correa-Munoz E, Mendoza- Nunez VM. Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. Bmc Musculoskeletal Disorders. 2007;8: 124.
11. Basu S, Michaelsson K, Olofsson H, Johansson S, Melhus H. Association between oxidative stress and bone mineral density. Biochemical and Biophysical Research Communications. 2001;288(1): 275-9.
12. Rebholz CM, Wu T, Hamm LL, et al. The association of plasma fluorescent oxidation products and chronic kidney disease: A casecontrol study. Am J Nephrol. 2012;36(4): 297-304.
13. Frankel EN. (ed.). Lipid oxidation, 2nd ed. Dundee, Scotland: The Oily Press LTD; 2005.
14. Wu TY, Willett WC, Rifai N, Rimm EB. Plasma fluorescent oxidation products as potential markers of oxidative stress for epidemiologic studies. American Journal of Epidemiology. 2007;166(5): 552-60.
15. Uttara B, Singh AV, Zamboni P, Mahajan RT. Oxidative stress and neurodegenerative diseases: A review of upstream and downstream antioxidant therapeutic options. Current Neuropharmacology. 2009;7(1): 65-74.
16. Wu TY, Rifai N, Roberts LJ, Willett WC, Rimm EB. Stability of measurements of biomarkers of oxidative stress in blood over 36 hours. Cancer Epidemiology Biomarkers & Prevention. 2004;13(8): 1399-402.
17. Colditz GA, Manson JE, Hankinson SE. The Nurses' Health Study: 20- year contribution to the understanding of health among women. Journal of Womens Health. 1997;6(1): 49-62.
18. Khalili H, Ananthakrishnan AN, Konijeti GG, Liao XM, Higuchi LM, Fuchs CS, et al. Physical activity and risk of inflammatory bowel disease: Prospective study from the Nurses' Health Study cohorts. Bmj-British Medical Journal. 2013;347: F6633.
19. Ascherio A, Hennekens C, Willett WC, Sacks F, Rosner B, Manson JA, et al. Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension. 1996;27(5): 1065-72.
20. Feskanich D, Willett WC, Colditz GA. Calcium, vitamin D, milk consumption, and hip fractures: A prospective study among postmenopausal women. American Journal of Clinical Nutrition. 2003;77(2): 504-11.
21. Zhang XH, Tworoger SS, Eliassen AH, Hankinson SE. Postmenopausal plasma sex hormone levels and breast cancer risk over 20 years of follow-up. Breast Cancer Research and Treatment. 2013;137(3): 883-92.
22. Farankel EN. Lipid oxidation. Dundee, Scotland: The Oily Press; 1998.
23. Rosner B, Cook N, Portman R, Daniels S, Falkner B. Determination of blood pressure percentiles in normal-weight children: Some methodological issues. American Journal of Epidemiology. 2008; 167(6): 653-66.
24. Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, Rosner B, et al. Validation of questionnaire information on risk-factors and disease outcomes in a prospective cohort study of women. American Journal of Epidemiology. 1986;123(5): 894-900.
25. Stanojkovic I, Kotur-Stevuljevic J, Spasic S, et al. Relationship between bone resorption, oxidative stress and inflammation in severe COPD exacerbation. Clinical Biochemistry. 2013;46(16-17): 1678-82.
26. Alfven T, Elinder CG, Hellstrom L, Lagarde F, Jarup L. Cadmium exposure and distal forearm fractures. J Bone Miner Res. 2004;19(6): 900-5.
27. Friberg L, Elinder C, Kjellstrom T, Nordberg GF. Cadmium and health: A toxicological and epidemiological appraisal Volume II: Effects and response, pp X; Size: Pages: 320. Boca Raton, FL, USA: CRC Press; 1985.
28. Khalil N, Cauley JA, Wilson JW, et al. Relationship of blood lead levels to incident nonspine fractures and falls in older women: The study of osteoporotic fractures. Journal of Bone and Mineral Research. 2008;23(9): 1417-25.
29. Randell AG, Nguyen TV, Bhalerao N, Silverman SL, Sambrook PN, Eisman JA. Deterioration in quality of life following hip fracture: A prospective study. Osteoporosis International. 2000;11(5): 460-6.
30. Osnes EK, Lofthus CM, Meyer HE, et al. Consequences of hip fracture on activities of daily life and residential needs. Osteoporosis International. 2004;15(7): 567-74.
31. Haentjens P, Autier P, Barette M, Boonen S, Belgian Hip Fracture Study G. The economic cost of hip fractures among elderly women. A one-year, prospective, observational cohort study with matched-pair analysis. Belgian Hip Fracture Study Group. The Journal of Bone and Joint Surgery American Volume. 2001;83-A(4): 493-500.
32. de Luise C, Brimacombe M, Pedersen L, Sorensen HT. Comorbidity and mortality following hip fracture: A population-based cohort study. Aging Clinical and Experimental Research. 2008;20(5): 412-8.
33. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet. 1999;353(9156): 878-82.
34. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359(9321): 1929-36.